Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CX11 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo group | PLACEBO_COMPARATOR | Placebo |
| CX11 Group A | EXPERIMENTAL | - |
| CX11 Group B | EXPERIMENTAL | - |
| CX11 Group C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CX11 | DRUG | CX11 tablets administered orally once daily (QD) with meals |
| Placebo | OTHER | Matching placebo tablets administered orally once daily (QD) with meals |
Inclusion Criteria: * Male or female, 18-55 years. * BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \<30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea. * Prior unsuccessful diet/exercise weight-loss attempt and stable body weight with...
CX11 is an investigational small molecule being developed for the treatment of Obesity & Overweight. It is currently in Phase 1 clinical development, with an active study evaluating its safety and tolerability in participants with these conditions.
The molecular target of CX11 has not been disclosed. It is a small molecule modality being investigated for its potential role in metabolic conditions, specifically Obesity & Overweight.
CX11 is being developed by Cytokinetics, Incorporated, a biopharmaceutical company publicly traded under the ticker CYTK.
CX11 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial is currently recruiting participants to evaluate its safety and tolerability.
CX11 is being studied in a Phase 1 clinical trial with the identifier NCT07652047. This randomized, double-blind, placebo-controlled study is evaluating the safety and tolerability of different doses of CX11 tablets in female participants aged 18 years and older with Obesity & Overweight in the United States.